wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q37958741-2BE0A402-6443-4FF0-89C5-9F30BAACDB3F
Q37958741-2BE0A402-6443-4FF0-89C5-9F30BAACDB3F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37958741-2BE0A402-6443-4FF0-89C5-9F30BAACDB3F
Novel options for the treatment of castration-resistant prostate cancer.
P2860
Q37958741-2BE0A402-6443-4FF0-89C5-9F30BAACDB3F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37958741-2BE0A402-6443-4FF0-89C5-9F30BAACDB3F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
fce0509d5c4fc98b1a4687d87f310b5ac565ba79
P2860
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.